Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease
暂无分享,去创建一个
[1] M. Hallett,et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.
[2] W. Jost. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration , 2014, Expert opinion on drug safety.
[3] J. Jankovic,et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. , 2014, Parkinsonism & related disorders.
[4] M. Galloway,et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. , 1989, Neurology.
[5] Regina Katzenschlager,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[6] P. Odin,et al. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.
[7] S. Factor,et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. , 2001, Archives of neurology.
[8] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[9] W. Ondo. IPX066, a mixed immediate/sustained-release levodopa preparation for Parkinson’s disease , 2014, Expert opinion on pharmacotherapy.
[10] M. Stacy,et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.
[11] W Poewe,et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.
[12] W. Poewe,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[13] D. Deleu,et al. Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease , 2002, Clinical pharmacokinetics.
[14] D. Nyholm,et al. Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women , 2010, European journal of neurology.
[15] Parkinson Study Group,et al. Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients , 1997, Annals of neurology.
[16] M. Sawada,et al. L-dopa therapy for Parkinson's disease: Past, present, and future , 2009 .
[17] Toshiharu Nagatsua,et al. L-dopa therapy for Parkinson's disease: past, present, and future. , 2009, Parkinsonism & related disorders.
[18] A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. , 2005, Archives of neurology.
[19] Fabrizio Stocchi,et al. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.
[20] W. Nelson,et al. Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism , 2013, The Patient - Patient-Centered Outcomes Research.
[21] L. Metman,et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[22] E. Tolosa,et al. Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study , 1999 .
[23] M. Schiess,et al. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. , 2000, Neurology.
[24] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[25] W. M. Chase,et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics , 2002, Neurology.
[26] J. Larsen,et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.
[27] U. Dillmann,et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. , 2014, Parkinsonism & related disorders.
[28] G. Deuschl,et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.